Humana (HUM) Price Target Raised to $305.00

Humana (NYSE:HUM) had its price objective increased by equities research analysts at Oppenheimer from $275.00 to $305.00 in a research report issued on Thursday. The firm presently has an “outperform” rating on the insurance provider’s stock. Oppenheimer’s price target indicates a potential upside of 14.96% from the company’s current price. Oppenheimer also issued estimates for Humana’s Q1 2018 earnings at $3.18 EPS and Q4 2019 earnings at $2.99 EPS.

HUM has been the topic of several other research reports. Credit Suisse Group reduced their price target on shares of Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. BMO Capital Markets lifted their price target on shares of Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. Jefferies Group reaffirmed a “hold” rating and set a $257.00 price target on shares of Humana in a research report on Friday, October 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $242.00 price target (down previously from $245.00) on shares of Humana in a research report on Thursday, November 9th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $230.00 price target on shares of Humana in a research report on Tuesday, December 5th. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $269.68.

Shares of Humana (NYSE HUM) opened at $265.32 on Thursday. The company has a market cap of $37,482.20, a P/E ratio of 22.44, a PEG ratio of 1.53 and a beta of 0.93. The company has a current ratio of 1.85, a quick ratio of 1.61 and a debt-to-equity ratio of 0.48. Humana has a 12-month low of $203.36 and a 12-month high of $293.35.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The firm had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. Humana had a net margin of 4.55% and a return on equity of 16.13%. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.34 EPS. analysts forecast that Humana will post 13.75 earnings per share for the current year.

Humana announced that its Board of Directors has initiated a share repurchase plan on Thursday, December 14th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the insurance provider to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

In other news, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the sale, the vice president now owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Brian P. Leclaire sold 1,679 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the sale, the senior vice president now directly owns 9,888 shares in the company, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. In the last three months, insiders sold 10,115 shares of company stock worth $2,501,627. 0.80% of the stock is owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. ARP Americas LP increased its position in shares of Humana by 192.9% during the fourth quarter. ARP Americas LP now owns 4,481 shares of the insurance provider’s stock worth $1,112,000 after acquiring an additional 2,951 shares during the period. Ontario Teachers Pension Plan Board increased its position in shares of Humana by 39.0% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 21,010 shares of the insurance provider’s stock worth $5,212,000 after acquiring an additional 5,891 shares during the period. American International Group Inc. increased its position in shares of Humana by 3.8% during the fourth quarter. American International Group Inc. now owns 56,870 shares of the insurance provider’s stock worth $14,108,000 after acquiring an additional 2,096 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Humana by 28.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 151,172 shares of the insurance provider’s stock worth $37,501,000 after acquiring an additional 33,100 shares during the period. Finally, Systematic Financial Management LP purchased a new stake in shares of Humana during the fourth quarter worth $19,100,000. 94.39% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.com-unik.info/2018/02/10/humana-hum-price-target-raised-to-305-00.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit